Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Non-cash Items (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non-cash Items for 13 consecutive years, with $907695.0 as the latest value for Q1 2026.

  • Quarterly Non-cash Items rose 1412.82% to $907695.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $907695.0 through Jan 2026, up 1412.82% year-over-year, with the annual reading at $917029.0 for FY2025, 275284.08% up from the prior year.
  • Non-cash Items for Q1 2026 was $907695.0 at PharmaCyte Biotech, up from $115071.0 in the prior quarter.
  • The five-year high for Non-cash Items was $917029.0 in Q2 2025, with the low at $333.0 in Q2 2024.
  • Average Non-cash Items over 5 years is $239926.6, with a median of $87535.5 recorded in 2025.
  • The sharpest move saw Non-cash Items tumbled 99.76% in 2024, then surged 275284.08% in 2025.
  • Over 5 years, Non-cash Items stood at $37603.0 in 2022, then surged by 649.77% to $281936.0 in 2023, then tumbled by 52.88% to $132859.0 in 2024, then fell by 13.39% to $115071.0 in 2025, then skyrocketed by 688.81% to $907695.0 in 2026.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $907695.0, $115071.0, and $175562.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.